GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma

ConclusionOur present data show anti-tumor effects mediated by dinutuximab beta against GBM cells providing a rationale for a GD2-directed immunotherapy against GBM. Due to high CRP expression, a combining of GD2-targeting with CRP blockade might be a further treatment option for GBM.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research